Every Form 4 that Dyne Therapeutics, Inc. (DYN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DYN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DYN filings page.
Dyne Therapeutics’ Chief Financial Officer Erick Lucera received new equity awards. On February 12, 2026, Lucera was granted 65,000 restricted stock units, each representing one share of common stock, at a grant price of $0. These RSUs are scheduled to vest in equal quarterly installments over four years starting May 12, 2026.
On the same date, Lucera also received a stock option covering 105,000 shares of common stock with an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030. Following the RSU grant, Lucera directly beneficially owns 131,100 unvested RSUs.
Dyne Therapeutics CEO and President, who is also a director, reported selling 2,662 shares of Common Stock on December 5, 2025 at a weighted average price of $20.72. The shares were automatically sold to satisfy tax withholding obligations tied to restricted stock units granted on December 4, 2024, under a restricted stock unit agreement that constitutes a binding contract consistent with the affirmative defense to liability under Rule 10b5-1, so the sale did not represent a discretionary trade.
After this transaction, the insider beneficially owns 196,877 shares directly, including 108,976 unvested RSUs, and 18,000 shares held in each of four trusts for the benefit of the reporting person’s children. The report notes that 2,662 shares were matchable under Section 16(b) with a prior purchase of 100,000 shares on July 14, 2025, and the reporting person has paid the issuer $31,111.88, representing the profit deemed realized on that short-swing transaction.
Dyne Therapeutics, Inc. (DYN) director Brian S. Posner received a stock option grant on 10/01/2025 for 70,000 shares with an exercise price of $12.50. The option is exercisable for underlying common stock and shows 70,000 shares beneficially owned following the grant, reported as direct ownership. The option vests over three years in equal monthly installments through 10/01/2028, giving the director continuing equity alignment over that period. The Form 4 was signed on 10/02/2025 by an attorney-in-fact on behalf of the reporting person.